IGFBP3 and GGT Biomarker Scoring for Chronic Liver Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-invasive tools for assessing chronic liver disease are not accurate enough to support patient management and require unnecessary invasive procedures, such as biopsies, and existing methods are not accurate enough to support patient management and facilitate the evaluation of new drugs.
Innovation Solution
The method involves determining the amount of the biomarkers insulin-like growth factor-binding protein 3 (IGFBP3) and gamma-glutamyltransferase (GGT) in a sample from said subject, and comparing the amounts of the insulin-like growth factor-binding protein 3 (IGFBP3) in a sample from said subject, and assessing chronic liver disease based on the comparison.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If liver biopsy is used to assess fibrosis, then diagnostic accuracy is improved, but patient safety and ease of operation deteriorate due to complications and invasive nature
Solution Approach 1:
The patent uses serum biomarkers (IGFBP3, GGT, and other liver function tests) as intermediary substances that reflect the actual fibrosis state without requiring direct tissue sampling. These biomarkers serve as mediators between the liver condition and diagnostic assessment, eliminating the need for invasive biopsy procedures while maintaining diagnostic capability.
Solution Approach 2:
The invention creates a computational model that copies the diagnostic information obtained from biopsy by combining multiple non-invasive serum biomarker measurements. The model reproduces the fibrosis assessment capability of biopsy through mathematical algorithms that process biomarker data, providing equivalent diagnostic value without physical tissue sampling.
2Measurement precision
If multiple biomarkers are combined to improve diagnostic accuracy, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The patent employs a universal computational model that can process multiple different biomarker combinations (IGFBP3, GGT, ALT, AST, platelet count, etc.) through a single integrated algorithm. This multi-functional approach allows the same assessment system to handle various biomarker sets, reducing overall system complexity compared to having separate models for each biomarker combination.
Solution Approach 2:
The invention transforms multiple biomarker measurements into a unified fibrosis score through parameter transformation using mathematical algorithms. By changing the parameters from individual biomarker values to a composite score, the system simplifies the interpretation process while maintaining the diagnostic information from all input biomarkers.
3Ease of operation
If non-invasive biomarker methods are used instead of biopsy, then ease of operation is improved, but measurement precision deteriorates due to insufficient accuracy
Solution Approach 1:
The patent merges multiple non-invasive biomarker measurements (IGFBP3, GGT, and standard liver function tests) into a unified diagnostic approach. By combining these biomarkers in a computational model, the method achieves diagnostic accuracy comparable to biopsy while maintaining the advantages of non-invasive sampling, thus resolving the accuracy deficit of individual non-invasive markers.
Data Source
AI summary
The present invention relates to a method for assessing chronic liver disease in a subject, said method comprising (a) determining an amount of the biomarker Insulin-like growth factor-binding protein 3 (IGFBP3) in a sample from said subject; (b) determining an amount of the biomarker gamma-glutamyltransferase (GGT) in said sample; (c) comparing the amounts of the biomarkers determined in steps (a) and (b) to references for said biomarkers and/or calculating a score for assessing chronic liver disease; and (d) assessing chronic liver disease in said subject based on the comparison and/or the calculation made in step (c). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.